Hermes Vector

Health

Apple and OpenEvidence launch health AI usage study in the U.S.

Apple has launched a virtual research study with OpenEvidence to examine how people interact with conversational health AI tools, open to up to 200,000 eligible U.S. participants aged 21 and older.

By Hermes Vector

Checked against 3 sourcesTechCrunchmezha.netmiragenews.com
Illustration for: Apple and OpenEvidence launch health AI usage study in the U.S.

In brief

  • Apple and OpenEvidence launched the Apple Health AI Usage Study in the United States.
  • The study is open to up to 200,000 eligible participants aged 21 and older with an iPhone 15 Pro or later running iOS 26 or later.
  • Study data will not be used to train AI models, and participants control whether to share HealthKit metrics or survey responses.
  • The app includes safety guardrails that suggest participants follow up with a provider for certain concerning questions.

Apple and OpenEvidence launch health AI usage study in the U.S.

Study launch

Apple has launched the Apple Health AI Usage Study in the United States, a virtual research study and associated app designed to advance understanding of how people interact with conversational health AI tools. The study is conducted in collaboration with OpenEvidence, a clinical AI platform used by healthcare professionals that generates answers using medical information from established sources, including The New England Journal of Medicine, Journal of the American Medical Association, and Nature.

Participation and requirements

The study is open to up to 200,000 eligible participants aged 21 and older across the United States. Participants need an Apple Intelligence-enabled iPhone 15 Pro or later running iOS 26 or later. They can download the study app to learn more and choose whether to enroll.

How the app works

Participants can ask the study app everyday health questions, explore complex medical information presented in approachable language, and view linked, peer-reviewed clinical citations supporting each response. They may also choose to share HealthKit data, including resting heart rate, activity, sleep or lab results, to explore how personal data affects the relevance and understanding of responses. The study will examine how health AI might help participants prepare for clinical visits with their doctors.

Privacy and safeguards

Study data will not be used to train AI models. Participants control whether to share HealthKit metrics or survey responses, and Apple says it has security measures to protect the study data it maintains and participants’ confidential information. The app’s safety guardrails are designed to detect certain concerning questions and suggest that participants follow up with a provider or other resources if needed.

Why it matters

Apple said the study aims to examine what drives user trust, the quality of responses, comprehension, and everyday health actions, to inform the responsible design of health AI experiences for Apple and the industry. Robert M. Wachter, M.D., UCSF’s professor and chair of the Department of Medicine, said: "Patients and clinicians are both turning to AI, but the tools they use are being built and tested in separate worlds. When patients and doctors draw on versions of the same trustworthy tools, patients arrive prepared, conversations improve, and next steps happen seamlessly. Connecting these tools, and rigorously studying what works, is how we’ll get there."


Sources

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.

Questions readers ask

Who is conducting the Apple Health AI Usage Study?
Apple has launched the study in collaboration with OpenEvidence, a clinical AI platform used by healthcare professionals.
What data can participants share with the study app?
Participants may choose to share HealthKit data, including resting heart rate, activity, sleep, or lab results, as well as survey responses.
Will the study data be used to train AI models?
No, study data will not be used to train AI models.
Why is this study important according to the article?
The study aims to examine what drives user trust, response quality, comprehension, and everyday health actions to inform the responsible design of health AI experiences.

The day's checked news, by email

One short email a day with the top stories. Free, and you can unsubscribe in one click.

Or follow for the latest news:

How do you feel about this story?

Comments 0

No comments yet. Start the discussion.

Health

FDA rejects Summit Therapeutics' Ivonescimab cancer drug

The FDA rejected Summit Therapeutics' Ivonescimab, a cancer drug invented by Akeso and licensed to Summit in a deal worth up to $5bn, citing insufficient evidence of effectiveness and no significant survival benefit.

Checked against 4 sourcesft.commlq.aibriefs.co+1 more